Q-omics provides the consensus-scored CCDC134 profile across patient tissues and cancer cell-line models. CCDC134 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC134 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, CCDC134 RNA expression shows 18,838 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where CCDC134 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC134 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC134 survival associations across molecular data types. CCDC134 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC134 RNA expression–survival associations across cancer types. High CCDC134 expression shows unfavorable associations in UVM, LIHC, BLCA and MESO, but favorable associations in SCLC and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC134 RNA expression.
This table summarizes CCDC134 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC134. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC134 shows higher tumor expression in BLCA, HNSC, LIHC, LUAD, STAD and LUSC. The BLCA box plot shows higher CCDC134 RNA expression in tumor versus normal tissue (log2 FC = +1.141, t-test p < 0.001).
This table shows molecular features associated with CCDC134 in patient tissues and cancer cell lines. In patient samples, CCDC134 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC134 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
